Skip to main content

Mylan's Generic EpiPen Reportedly Ready by End of Year

Mylan's generic EpiPen will come this year, but later than originally expected.

Just when you thought Mylan's (MYL) - Get Viatris, Inc. Report EpiPen controversy had subsided, it resurfaces. The company's half-price version of its life-saving allergy treatment will be available by the end of this year, potentially months later than a timeline Mylan gave in August, according to Bloomberg. The cheaper version of the EpiPen shot will cost $300. Mylan spokeswoman Nina Devlin told Bloomberg that Mylan expected the so-called authorized generic EpiPen this year, "once we have assured that sufficient inventory will be available to meet anticipated orders."

Employees of TheStreet are restricted from trading individual securities.

Scroll to Continue

TheStreet Recommends